Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 687604108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
RTW Investments, LP
13G
|
5.2% |
8/14/2026
Event 6/30/2026
|
|
| RTW Investments, LP | 5.2% | ||
| Roderick Wong | 5.2% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 4
|
7.4% |
8/14/2026
Event 6/30/2026
|
|
| Venrock Healthcare Capital Partners III, L.P. | 7.4% | ||
| VHCP Co-Investment Holdings III, LLC | 7.4% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 7.4% | ||
| VHCP Management III, LLC | 7.4% | ||
| VHCP Management EG, LLC | 7.4% | ||
| Nimish Shah | 7.4% | ||
| Bong Y. Koh | 7.4% | ||
|
Viking Global Investors LP
13G/A
Amendment 2
|
2.5% |
8/14/2026
Event 6/30/2026
|
|
| Viking Global Investors LP | 2.5% | ||
| Viking Global Opportunities Parent GP LLC | 2.5% | ||
| Viking Global Opportunities GP LLC | 1.5% | ||
| Viking Global Opportunities Portfolio GP LLC | 1.5% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.5% | ||
| Viking Global Opportunities Drawdown GP LLC | 1.0% | ||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.0% | ||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.0% | ||
| Halvorsen Ole Andreas | 2.5% | ||
| Shabet Rose Sharon | 2.5% | ||
| Capital World Investors 13G | 5.6% |
8/12/2026
Event 6/30/2026
|
|
|
Fairmount Funds Management LLC
13D/A
Amendment 6
|
19.5% |
7/1/2026
Event 7/1/2026
|
|
| Fairmount Funds Management LLC | 19.5% | ||
| Fairmount Healthcare Fund II L.P. | 16.0% | ||
| Fairmount Healthcare Co-Invest III L.P. | 4.0% | ||
| Harwin Peter Evan | 19.5% | ||
| Kiselak Tomas | 19.5% | ||
|
Viking Global Investors LP
13G/A
Amendment 1
|
5.3% |
5/15/2026
Event 3/31/2026
|
|
| Viking Global Investors LP | 5.3% | ||
| Viking Global Opportunities Parent GP LLC | 5.3% | ||
| Viking Global Opportunities GP LLC | 3.2% | ||
| Viking Global Opportunities Portfolio GP LLC | 3.2% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 3.2% | ||
| Viking Global Opportunities Drawdown GP LLC | 2.1% | ||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.1% | ||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.1% | ||
| Halvorsen Ole Andreas | 5.3% | ||
| Shabet Rose Sharon | 5.3% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 5
|
20.0% |
5/4/2026
Event 4/30/2026
|
|
| Fairmount Funds Management LLC | 20.0% | ||
| Fairmount Healthcare Fund II L.P. | 16.2% | ||
| Fairmount Healthcare Co-Invest III L.P. | 4.4% | ||
| Harwin Peter Evan | 20.0% | ||
| Kiselak Tomas | 20.0% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
RTW Investments, LP
13G/A
Amendment 1
|
4.3% |
2/17/2026
Event 12/31/2025
|
|
| RTW Investments, LP | 4.3% | ||
| Roderick Wong | 4.3% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
4.5% |
2/13/2026
Event 12/31/2025
|
|
| Deep Track Capital, LP | 4.5% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 3.9% | ||
| David Kroin | 4.5% | ||
| Deep Track Special Opportunities Fund, LP. | 0.5% | ||
| Vanguard Group Inc 13G | 5.1% |
1/30/2026
Event 12/31/2025
|
|
| BlackRock, Inc. 13G | 6.6% |
1/21/2026
Event 12/31/2025
|
|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 3
|
9.9% |
11/14/2025
Event 9/30/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||
| VHCP Management III, LLC | 9.9% | ||
| VHCP Management EG, LLC | 9.9% | ||
| Nimish Shah | 9.9% | ||
| Bong Y. Koh | 9.9% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.5% |
10/17/2025
Event 9/30/2025
|
|
|
Viking Global Investors LP
13G
|
5.5% |
9/24/2025
Event 9/17/2025
|
|
| Viking Global Investors LP | 5.5% | ||
| Viking Global Opportunities Parent GP LLC | 5.5% | ||
| Viking Global Opportunities GP LLC | 3.3% | ||
| Viking Global Opportunities Portfolio GP LLC | 3.3% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 3.3% | ||
| Viking Global Opportunities Drawdown GP LLC | 2.2% | ||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.2% | ||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.2% | ||
| Halvorsen Ole Andreas | 5.5% | ||
| Ott David C. | 5.5% | ||
| Shabet Rose Sharon | 5.5% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 4
|
20.0% |
9/19/2025
Event 9/17/2025
|
|
| Fairmount Funds Management LLC | 20.0% | ||
| Fairmount Healthcare Fund II L.P. | 15.4% | ||
| Fairmount Healthcare Co-Invest III L.P. | 5.3% | ||
| Peter Evan Harwin | 20.0% | ||
| Tomas Kiselak | 20.0% | ||
| BlackRock, Inc. 13G | 5.3% |
7/17/2025
Event 6/30/2025
|
|
|
RTW Investments, LP
13G
|
5.2% |
5/15/2025
Event 3/31/2025
|
|
| RTW Investments, LP | 5.2% | ||
| Roderick Wong, M.D. | 5.2% | ||
|
Deep Track Capital, LP
13G
|
5.1% |
5/13/2025
Event 5/6/2025
|
|
| Deep Track Capital, LP | 5.1% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 5.1% | ||
| David Kroin | 5.1% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 3
|
20.0% |
3/10/2025
Event 3/6/2025
|
|
| Fairmount Funds Management LLC | 20.0% | ||
| Fairmount Healthcare Fund II L.P. | 14.0% | ||
| Fairmount Healthcare Co-Invest III L.P. | 6.9% | ||
| Peter Evan Harwin | 20.0% | ||
| Tomas Kiselak | 20.0% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 2
|
11.1% |
2/27/2025
Event 2/10/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 11.1% | ||
| VHCP Co-Investment Holdings III, LLC | 11.1% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 11.1% | ||
| VHCP Management III, LLC | 11.1% | ||
| VHCP Management EG, LLC | 11.1% | ||
| Nimish Shah | 11.1% | ||
| Bong Y Koh | 11.1% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 542 | $45.1 k |
| 2026 Q2 | 265 | 77.6 M | $7.09 B |
| 2026 Q1 | 190 | 52.9 M | $2.61 B |
| 2025 Q4 | 146 | 52.9 M | $1.56 B |
| 2025 Q3 | 111 | 45.6 M | $876 M |
| 2025 Q2 | 83 | 34.6 M | $387 M |
| 2025 Q1 | 72 | 31.8 M | $326 M |
| 2024 Q4 | 67 | 31.0 M | $607 M |
| 2024 Q3 | 44 | 24.6 M | $604 M |